Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates.
New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.
BR regimen shows survival outcomes in newly diagnosed Waldenstroms Macroglobulinemia patients
A Rare Blood Cancer With an 8-Year Survival: What Real-World Data Shows
This single-center retrospective analysis evaluated 89 newly diagnosed Waldenstroms Macroglobulinemia patients treated with the BR regimen. …
New real-world data shows patients with the rare blood cancer Waldenstrom's macroglobulinemia live a median of over 8 years after diagnosis.
Narrative review outlines clinical framework for managing primary Sjögren's disease with interstitial lung disease
New Hope for Sjögren's Patients with Lung Scarring
A narrative review synthesizes evidence on managing primary Sjögren's disease with interstitial lung disease, highlighting a pragmatic clini…
Lung scarring in Sjögren's disease can be deadly, but new strategies targeting specific disease patterns offer a path forward for patients.
RCD chemotherapy in Waldenström macroglobulinemia with AL amyloidosis led to rapid progression and death.
Rare Blood Cancer Causes Fast Kidney Failure
This case report and literature review describes a 75-year-old female with Waldenström macroglobulinemia and AL lambda-type amyloid nephropa…
When a rare blood cancer attacks the kidneys, standard treatments often fail to stop the fast progression to organ failure.
Rituximab exposure is associated with serum sickness in patients with multiple sclerosis, nephrotic syndrome, or immune thrombocytopenia.
Can taking Rituximab cause a severe allergic reaction that returns if you take it again?
This retrospective review analyzed 39 published case reports of patients with rituximab-induced serum sickness (RISS). The study describes c…
Taking Rituximab can trigger a delayed allergic reaction that returns in most patients if the drug is given again, so doctors must use extre…
Therapeutic plasma exchange in pediatric autoimmune diffuse alveolar hemorrhage shows 5 of 6 survival
Kids' Lungs Bleeding: Early Blood Swap Saves Lives
A retrospective cohort study of 6 pediatric patients with autoimmune diffuse alveolar hemorrhage requiring intensive care found that therape…
Early blood swaps saved six critically ill children with autoimmune lung bleeding, avoiding death in all cases treated with this urgent ther…
Phase 2 trial compares Inotuzumab Ozogamicin plus R-CVP for DLBCL patients unfit for anthracycline
Can a new drug combination help lymphoma patients who can't take standard chemo?
A Phase 2 interventional trial enrolled 129 patients with diffuse large B-cell lymphoma (DLBCL) who were unsuitable for anthracycline-contai…
A new drug combo aims to treat aggressive lymphoma in older patients who can't take standard chemo due to heart risks.
Case report: Orelabrutinib-rituximab with intravitreal methotrexate shows response in primary vitreoretinal lymphoma
Can a new drug combination help treat a rare eye cancer?
A case report with literature review describes one patient with primary vitreoretinal lymphoma (PVRL) treated with orelabrutinib and rituxim…
A new drug combination improved vision and controlled tumors in a patient with a rare eye cancer, with no reported side effects.
Rituximab with prednisone reduced proteinuria in Sjögren's syndrome-associated membranous nephropathy case
Rituximab treatment reduced kidney protein loss in one Sjögren's syndrome patient
A case report describes a 48-year-old female with primary Sjögren's syndrome and nephrotic-range proteinuria treated with prednisone and rit…
A 48-year-old woman with Sjögren's syndrome saw her kidney protein loss drop from 8.5 to 2.2 grams after receiving rituximab treatment.
Obinutuzumab induced remission in FSGS patient after rituximab failure in case report
Obinutuzumab helped one patient with kidney disease after rituximab did not work
A case report describes a 33-year-old woman with primary FSGS and nephrotic syndrome who achieved complete remission after obinutuzumab foll…
When rituximab failed to stop protein leakage in a kidney disease patient, a single dose of obinutuzumab restored remission without side eff…